Advertisement


Jeffrey E. Lancet, MD, on AML: Subgroup Analysis of a Phase III Trial

2016 ASH Annual Meeting & Exposition

Advertisement

Jeffrey E. Lancet, MD, of the H. Lee Moffitt Cancer Center and Research Institute, discusses study findings on survival following allogeneic hematopoietic cell transplantation in older, high-risk acute myeloid leukemia patients initially treated with CPX-351 liposome injection vs standard cytarabine and daunorubicin (Abstract 906).



Related Videos

Lymphoma

Umberto Vitolo, MD, and Sagar Lonial, MD, on DLBCL: Final Results From the GOYA Trial

Umberto Vitolo, MD, of Città della Salute e della Scienza Hospital and University, and Sagar Lonial, MD, of Emory University, discuss study findings on obinutuzumab o...

Lymphoma

Robert E. Marcus, MD, on Follicular Lymphoma: Results From the GALLIUM Trial

Robert E. Marcus, MD, of Kings College Hospital, discusses study findings on obinutuzumab-based induction and maintenance in patients with previously untreated disease (Abstract 6).

Lymphoma
Geriatric Oncology

Catherine Thieblemont, MD, PhD, and Julie Vose, MD, MBA, on DLBCL: Results From the Lysa Remarc Study

Catherine Thieblemont, MD, PhD, of Hôpital Saint-Louis and INSERM, and Julie Vose, MD, MBA, of the University of Nebraska Medical Center, discuss phase III trial find...

Leukemia

Jose F. Leis, MD, PhD, and Sagar Lonial, MD, on CLL: Ibrutinib Insights

Jose F. Leis, MD, PhD, of the Mayo Clinic, and Sagar Lonial, MD, of Emory University, discuss a session on CLL treatment (excluding transplantation): ibrutinib resist...

Leukemia

Harry P. Erba, MD, PhD, on AML: Early Study Results on Vadastuximab Talirine

Harry P. Erba, MD, PhD, of the University of Alabama at Birmingham, discusses phase Ib findings on vadastuximab talirine in combination with 7+3 induction therapy for patients with ne...

Advertisement

Advertisement



Advertisement